EURURO Vol. 72 No. 3

328 476

[3] Eapen RS, Herlemann A, Washington SL, CooperbergMR. Impact of the
United States Preventive Services Task Force ‘‘D’’ recommendation on
prostate cancer screening and staging. Curr Opin Urol 2017;27:205–9
[4] Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA
testing patterns in relation to USPSTF screening recommendations.
JAMA 2015;314:2054–61
[5] Barocas DA, Mallin K, Graves AJ, et al. Effect of the USPSTF grade D
recommendation against screening for prostate cancer on incident
prostate cancer diagnoses in the United States. J Urol
2015;194:1587–93
[6] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin
2017;67:7–30
[7] Kaffenberger SD, Penson DF. The politics of prostate cancer screen-
ing. Urol Clin North Am 2014;41:249–55
[8] US Preventive Services Task Force. Draft recommendation state-
ment: prostate cancer: screening. USPSTF; 2017.
[9]
[10] Schro¨der FH, Hugosson J, Roobol MJ, et al. Screening and prostate
cancer mortality: results of the European Randomised Study of
Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
Lancet 2014;384:2027–35
[11] [48_TD$DIFF] [49_TD$DIFF] [50_TD$DIFF]
[51_TD$DIFF] [52_TD$DIFF] [53_TD$DIFF]
[12] Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J.
Opportunistic testing versus organized prostate-specific antigen
screening: outcome after 18 years in the Go¨teborg randomized
population-based prostate cancer screening trial. Eur Urol
2015;68:354–60
[13] Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate
cancer: AUA guideline. J Urol 2013;190:419–26
[14] Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of
prostate cancer based on relation between prostate specific antigen
at age 40-55 and long term risk of metastasis: case-control study.
BMJ 2013;346:f2023–33
[15] Preston MA, Batista JL, Wilson KM, et al. Baseline prostate-specific
antigen levels in midlife predict lethal prostate cancer. J Clin Oncol
2016;34:2705–11
[16] Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ.
What is the true number needed to screen and treat to save a life
with prostate-specific antigen testing? J Clin Oncol 2011;29:464–7
[17] Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R. Long-term projec-
tions of the harm-benefit trade-off in prostate cancer screening are
more favorable than previous short-term estimates. J Clin Epide-
miol 2011;64:1412–7
[18] Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. Screening men
at increased risk for prostate cancer diagnosis: model estimates of
benefits and harms. Cancer Epidemiol Biomarkers Prev
2017;26:222–7
[19] Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long-
term health-related quality of life after primary treatment for
localized prostate cancer: results from the CaPSURE registry. Eur
Urol 2015;68:600–8
[20] Resnick MJ, Koyama T, Fan K-H, et al. Long-term functional out-
comes after treatment for localized prostate cancer. N Engl J Med
2013;368:436–45
[21] Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction
with outcome among prostate-cancer survivors. N Engl J Med
2008;358:1250–61
[22] Ficarra V, Novara G, Ahlering TE, et al. Systematic review and meta-
analysis of studies reporting potency rates after robot-assisted
radical prostatectomy. Eur Urol 2012;62:418–30
[23] Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta-
analysis of studies reporting urinary continence recovery after
robot-assisted radical prostatectomy. Eur Urol 2012;62:405–17
[24] Tewari A, Sooriakumaran P, Bloch DA, Seshadri-Kreaden U, Hebert
AE, Wiklund P. Positive surgical margin and perioperative compli-
cation rates of primary surgical treatments for prostate cancer: a
systematic review and meta-analysis comparing retropubic, lapa-
roscopic, and robotic prostatectomy. Eur Urol 2012;62:1–15
[25] Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally
invasive vs open radical prostatectomy. JAMA 2009;302:1557–64
[26] Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao S-L.
Fifteen-year outcomes following conservative management among
men aged 65 years or older with localized prostate cancer. Eur Urol
2015;68:805–11
[27] Cooperberg MR, Broering JM, Carroll PR. Risk assessment for pros-
tate cancer metastasis and mortality at the time of diagnosis. J Natl
Cancer Inst 2009;101:878–87
[28] Prabhu V, Lee T, Loeb S, et al. Twitter response to the United States
Preventive Services Task Force recommendations against screening
with prostate-specific antigen. BJU Int 2015;116:65–71
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 2 6 – 3 2 8 328